Media

Cramer Wants to Go Back Into An Old Stock

Cramer on tonight’s MAD MONEY was discussing a stock that was taken off the table after it ran huge.   Cramer thinks that Syneron Medical (ELOS) really has the laser we’re all looking for.  He said he swaped out of it before in favor of Palomar (PMTI), but since it fell from $40 to under $25 it is cheap.  There is a catalyst coming next month that could reverse the stock drop after two bad earnings misses from higher expenses.  ELOS rolls out a dental laser next month that isn’t just cosmetic.  This one does the same thing as drilling teeth and there are 200,000 dentists versus 18,000 dermatologists.

ELOS was up a mysterious 6.8% today to $25.70 on 4-times normal volume.  Did one of Cramer’s cronies doll out a stock tip into people’s Christmas stockings or in place of Hanukkah dradles today?  This stock is up another 4.4% in after-Cramer hours.

Cramer said rumors were out there today that the company would be acquired by Allergan (AGN), so that is his explanation for the run today.  He thinks the buyer could be anyone since the company has only a $700M market cap.  He thinks the worst is over.  He nailed it once and said to take profits, but now he wants you back into ELOS.

Jon C. Ogg
December 20, 2006

Essential Tips for Investing: Sponsored

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.